HEMODILUTION AND CEREBRAL ISCHEMIA

这个项目的目的是研究中风的治疗方法。 使用基础研究技术的血液稀释。目前使用的是 使用低分子右旋糖苷(LMWD)进行血液稀释的 正在临床试验中进行评估。血液稀释和 急性卒中的血液浓缩将使用 局灶性脑缺血动物模型及双标记法 放射自显影技术测定局部脑血 同一脑组织的血流量(LCBF)和局部脑pH(LCpH) 一节。数据分析将集中在LCBF的测量上， 解剖部位的LC pH及其比值。的边境区 缺血区将被评估为血液稀释的区域 可能会影响中风的结局。血液稀释和 血液浓缩将用于慢性卒中模型和 使用神经病理学和放射自显影进行评估 标准。动物将在各种血细胞中进行研究，以发现 最佳红细胞压积水平。等离子体和LMWD都将是 用作血液稀释剂，以发现任何特定的有益效果 低分子肝素对卒中结局的抑制作用 红血球和血小板聚集。

The aim of this project is to study the treatment of stroke with hemodilution using basic research techniques. Currently the use of hemodilution with low molecular weight dextran (LMWD) is being evaluated in clinical trials. Hemodilution and hemoconcentration will be evaluated in acute stroke using an animal model of focal cerebral ischemia and the double label autoradiographic technique for determining local cerebral blood flow (LCBF) and local cerebral pH (LCpH) in the same brain section. Data analysis will focus on the measurement of LCBF, LCpH and their ratio in anatomical regions. The border zone of the ischemic area will be evaluated as an area where hemodilution could effect stroke outcome. Hemodilution and hemoconcentration will be used in a chronic model of stroke and evaluated using both neuropathological and autoradiographic criteria. Animals will be studied at various hematocrits to find the optimal hematocrit level. Both plasma and LMWD will be used as hemodilutants to uncover any specific, beneficial effect of LMWD on stroke outcome due to its properties as an inhibitor of red cell and platelet aggregation.